KEYNOTE-522: Phase III study of pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo (pbo) plus chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC)

被引：0
|
作者：
Schmid, P. [1 ]
Cortes, J. [2 ,3 ,4 ]
Dent, R. [5 ]
Pusztai, L. [6 ]
McArthur, H. L. [7 ]
Kuemmel, S. [8 ]
Bergh, J. [9 ,10 ]
Denkert, C. [11 ]
Park, Y. H. [12 ]
Hui, R. [13 ,14 ]
Harbeck, N. [15 ]
Takahashi, M. [16 ]
Foukakis, T. [9 ,10 ]
Fasching, P. A. [17 ]
Cardoso, F. [18 ]
Jia, L. [19 ]
Karantza, V. [20 ]
Zhao, J. [21 ]
Aktan, G. [20 ]
O'Shaughnessy, J. [22 ]
机构：
[1] Queen Mary Univ London, Barts Canc Inst, Ctr Expt Canc Med, London, England
[2] IOB Inst Oncol, Quironsalud Grp, Oncol Dept, Madrid, Spain
[3] IOB Inst Oncol, Quironsalud Grp, Oncol Dept, Barcelona, Spain
[4] Vall dHebron Intitute Oncol VHIO, Barcelona, Spain
[5] Univ Toronto, Toronto, ON, Canada
[6] Yale Univ, Sch Med, Yale Canc Ctr, New Haven, CT USA
[7] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Los Angeles, CA 90048 USA
[8] Kliniken Essen Mitte Evang, Breast Unit, Essen, Germany
[9] Karolinska Inst, Dept Oncol Pathol, Solna, Sweden
[10] Karolinska Univ Hosp, Breast Canc Ctr, Canc Theme, Solna, Sweden
[11] Philipps Univ Marburg, Inst Pathol, Marburg, Germany
[12] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Hematol Oncol, Seoul, South Korea
[13] Westmead Hosp, Dept Med Oncol, Sydney, NSW, Australia
[14] Univ Sydney, Sydney, NSW, Australia
[15] Univ Munich LMU, Breast Ctr, Dept Gynecol & Obstet, Munich, Germany
[16] NKO Hokkaido Canc Ctr, Dept Breast Surg, Sapporo, Hokkaido, Japan
[17] Friedrich Alexander Univ Erlangen Nuremberg, Univ Hosp Erlangen, Comprehens Canc Ctr Erlangen EMN, Gynecol & Obstet, Erlangen, Germany
[18] Champalimaud Fdn, Breast Unit, Canc Ctr, Lisbon, Portugal
[19] Merck & Co Inc, Biostat, Kenilworth, NJ USA
[20] Merck & Co Inc, Dept Oncol, Kenilworth, NJ USA
[21] Merck & Co Inc, Biostat, N Wales, PA USA
[22] Baylor Univ, Med Ctr, Breast Oncol, Dallas, TX USA
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA8_PR
引用
收藏
页码：853 / 854
页数：2
相关论文
共 50 条
  • [1] KEYNOTE-522 Asian subgroup: Phase III study of neoadjuvant pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (chemo) followed by adjuvant pembro vs pbo for early triple-negative breast cancer (TNBC)
    Dent, R.
    Cortes, J.
    Pusztai, L.
    McArthur, H. L.
    Kuemmel, S.
    Bergh, J.
    Denkert, C.
    Park, Y. H.
    Hui, R.
    Harbeck, N.
    Takahashi, M.
    Foukakis, T.
    Fasching, P. A.
    Cardoso, F.
    Jia, L.
    Jensen, E.
    Karantza, V.
    Aktan, G.
    O'Shaughnessy, J.
    Schmid, P.
    ANNALS OF ONCOLOGY, 2020, 31 : S1241 - S1242
  • [2] KEYNOTE-522: Phase III study of pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as neoadjuvant therapy followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC).
    Schmid, Peter
    Cortes, Javier
    Bergh, Jonas C. S.
    Pusztai, Lajos
    Denkert, Carsten
    Verma, Sunil
    McArthur, Heather L.
    Kummel, Sherko
    Ding, Yu
    Karantza, Vassiliki
    Dang, Thao
    Dent, Rebecca Alexandra
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [3] KEYNOTE-522: Phase III study of pembrolizumab (pembro) 1 chemotherapy (chemo) vs placebo 1 chemo as neoadjuvant followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC)
    Schmid, P.
    Cortes Castan, J.
    Bergh, J.
    Pusztai, L.
    Denkert, C.
    Verma, S.
    McArthur, H. L.
    Zhao, J.
    Aktan, G.
    Dang, T.
    Dent, R.
    ANNALS OF ONCOLOGY, 2017, 28
  • [4] KEYNOTE-522 Study of Pembro plus Chemo vs. Placebo plus Chemo as Neoadjuvant Treatment Followed by Pembro vs. Placebo as Adjuvant Treatment for Early TNBC: Pathologic Complete Response in Key Subgroups
    Schmid, P.
    ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (SUPPL 1) : S129 - S129
  • [5] KEYNOTE-522: Neoadjuvant Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy Followed by Adjuvant Pembrolizumab vs Placebo for Early-stage Triple Negative Breast Cancer
    McArthur, Heather
    Cortes, Javier
    Dent, Rebecca
    Pusztai, Lajos
    Kuemmel, Sherko
    Bergh, Jonas
    Denkert, Carsten
    Park, Yeon Hee
    Hui, Rina
    Harbeck, Nadia
    Takahashi, Masato
    Untch, Michael
    Fasching, Peter A.
    Cardoso, Fatima
    Andersen, Jay
    Patt, Debra
    Danso, Michael
    Ferreira, Marta
    Mouret-Reynier, Marie-Ange
    Im, Seock-Ah
    Ahn, Jin-Hee
    Gion, Maria
    Baron-Hay, Sally
    Boileau, Jean-Francois
    Zhu, Yalin
    Pan, Wilbur
    Tryfonidis, Konstantinos
    Karantza, Vassiliki
    O'Shaughnessy, Joyce
    Schmid, Peter
    ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (SUPPL 2) : 338 - 338
  • [6] Neoadjuvant pembrolizumab plus chemotherapy vs placebo plus chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: surgical outcomes from the phase 3 KEYNOTE-522 study
    Kuemmel, S.
    Schmid, P.
    Harbeck, N.
    Takahashi, M.
    Untch, M.
    Boileau, J. -F.
    Cortes, J.
    McArthur, H.
    Dent, R.
    O'Shaughnessy, J.
    Pusztai, L.
    Foukakis, T.
    Park, Y. H.
    Hui, R.
    Cardoso, F.
    Denkert, C.
    Zhu, Y.
    Pan, W.
    Karantza, V.
    Fasching, P.
    BREAST, 2023, 68 : S63 - S64
  • [7] Neoadjuvant Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy Followed by Adjuvant Pembrolizumab vs Placebo for Early TNBC: Surgical Outcomes from the Phase 3 KEYNOTE-522 Study
    Kuemmel, Sherko
    Schmid, Peter
    Harbeck, Nadia
    Takahashi, Masato
    Untch, Michael
    Boileau, Jean-Francois
    Cortes, Javier
    McArthur, Heather
    Dent, Rebecca
    O'Shaughnessy, Joyce
    Pusztai, Lajos
    Foukakis, Theodoros
    Park, Yeon Hee
    Hui, Rina
    Cardoso, Fatima
    Denkert, Carsten
    Zhu, Yalin
    Pan, Wilbur
    Karantza, Vassiliki
    Fasching, Peter A.
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (SUPPL 2) : S295 - S296
  • [8] Safety evaluation from the KEYNOTE-522 study of neoadjuvant pembrolizumab (or placebo) plus chemotherapy followed by adjuvant pembrolizumab (or placebo) in patients with early triple-negative breast cancer (TNBC)
    Cortes, Javier
    Dent, Rebecca
    Pusztai, Lajos
    McArthur, Heather
    Kuemmel, Sherko
    Denkert, Carsten
    Park, Yeon Hee
    Hui, Rina
    Takahashi, Masato
    Barrios, Carlos
    Zhu, Yalin
    Zhang, Xiaoli
    Pan, Wilbur
    Karantza, Vassiliki
    O'Shaughnessy, Joyce
    Schmid, Peter
    CANCER RESEARCH, 2024, 84 (09)
  • [9] Phase III study of neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer (TNBC): KEYNOTE-522 Korean subgroup analysis
    Park, Y. H.
    Im, S-A.
    Ahn, J-H.
    Kim, M. H.
    Cortes, J.
    Dent, R. A.
    Pusztai, L.
    McArthur, H. L.
    Kummel, S.
    Denkert, C.
    O'Shaughnessy, J.
    Mouret-Reynier, M-A.
    Ferreira, M. I. R.
    Cortes, M. Gion
    Boileau, J-F.
    Hui, R.
    Zhu, Y.
    Pan, W.
    Karantza, V. V.
    Schmid, P.
    ANNALS OF ONCOLOGY, 2023, 34 : S1467 - S1468
  • [10] Pembrolizumab (pembro) plus chemotherapy (chemo) as neoadjuvant treatment for triple negative breast cancer (TNBC): Preliminary results from KEYNOTE-173
    Schmid, Peter
    Park, Yeon Hee
    Munoz-Couselo, Eva
    Kim, Sung-Bae
    Sohn, Joohyuk
    Im, Seock-Ah
    Holgado, Esther
    Wang, Yang
    Dang, Thao
    Aktan, Gursel
    Cortes, Javier
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345